Policy | November 11, 2025
Trump clinches historic deal as Lilly, Novo slash U.S. weight-loss drug prices
Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans
Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans
The discussions come as part of the administration’s broader efforts to drive down drug prices and increase patient access to essential therapies
Approval based on pivotal KOMET Phase III trial demonstrating significant tumour reduction in adults with NF1
New Phase III data on gefurulimab highlight potential as a self-administered treatment option; real-world evidence reinforces clinical benefits of Ultomiris and Soliris
Ticagrelor tablets are indicated for reducing the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
Datroway becomes the first and only therapy to show overall survival benefit versus chemotherapy in this difficult-to-treat patient population
Miels will formally assume the role on January 1, 2026
Second positive Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu in HER2-positive early breast cancer reinforces its potential to become a foundational treatment option in curative-intent setting
_256_384.jpg)
Marksans Pharma gets USFDA nod for acid reflux drug
Subscribe To Our Newsletter & Stay Updated
